The overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer results in more aggressive disease with a poor prognosis. The more active combination for human HER2 in breast cancer is anti-HER2 monoclonal antibodies pertuzumab and Trastuzumab since they comprehensively block signaling pathway. A combination therapy was investigated for HER2-positive metastatic breast cancer in the Clinical Evaluation of pertuzumab and Trastuzumab trial along with docetaxel as a first-line treatment.
This study reported that the combination therapy significantly improved progression-free survival of human HER2 with pertuzumab, trastuzumab, and docetaxel in comparison to placebo, trastuzumab, and docetaxel. In this randomized, double-blind, placebo-controlled, phase 3 trial for 50 months, patients with an age of 18 years or above with metastatic HER2-positive breast cancer that…
